The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

25 analysts have shared their evaluations of Vertex Pharmaceuticals (NASDAQ:VRTX) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday.

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing in the development of innovative therapies for serious diseases.

As of 2:47:43 PM EST. Market Open. Key Insights Using the 2 Stage Free Cash Flow to Equity, Vertex Pharmaceuticals fair value estimate is US$706 Vertex... To illustrate that point, let's discuss ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...

Right to work is one of four different pieces of legislation that would change collective bargaining laws for Ohio's public ...